Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(COV) stock logo
COV
(COV)
$0.00
$65.97
$108.57
N/AN/A3.88 million shsN/A
Medicure Inc. stock logo
MPH
Medicure
C$0.99
-3.9%
C$1.15
C$0.99
C$1.80
C$10.15M1.014,370 shs3,300 shs
Optec International, Inc. stock logo
OPTI
Optec International
$0.00
$0.00
$0.00
$0.00
$43KN/A41.41 million shs13.91 million shs
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
$2.13
+3.9%
$2.04
$0.95
$8.95
$40.39M0.6738,664 shs1,134 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(COV) stock logo
COV
(COV)
0.00%0.00%0.00%0.00%0.00%
Medicure Inc. stock logo
MPH
Medicure
0.00%-8.33%-13.91%-13.91%-23.85%
Optec International, Inc. stock logo
OPTI
Optec International
+15.63%+8.82%+23.33%+270.00%+825.00%
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-0.49%+3.02%+3.54%+4.06%-67.65%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/AN/AN/A
Medicure Inc. stock logo
MPH
Medicure
N/AN/AN/AN/AN/AN/AN/AN/A
Optec International, Inc. stock logo
OPTI
Optec International
N/AN/AN/AN/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
3.0628 of 5 stars
3.54.00.00.03.61.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(COV) stock logo
COV
(COV)
N/AN/AN/AN/A
Medicure Inc. stock logo
MPH
Medicure
N/AN/AN/AN/A
Optec International, Inc. stock logo
OPTI
Optec International
N/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
3.00
Buy$8.00275.59% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/AN/A
Medicure Inc. stock logo
MPH
Medicure
C$22.94M0.44C$0.40 per share2.49C$2.10 per share0.47
Optec International, Inc. stock logo
OPTI
Optec International
N/AN/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
$10K4,038.48N/AN/A$0.20 per share10.65

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(COV) stock logo
COV
(COV)
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Medicure Inc. stock logo
MPH
Medicure
C$1.08MC$0.0911.00N/A4.71%5.04%2.49%5/24/2024 (Estimated)
Optec International, Inc. stock logo
OPTI
Optec International
N/AN/A0.00N/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)

Latest TILS, PMN, MPH, COV, and OPTI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/A-$0.09-$0.09-$0.09N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(COV) stock logo
COV
(COV)
N/AN/AN/AN/AN/A
Medicure Inc. stock logo
MPH
Medicure
N/AN/AN/AN/AN/A
Optec International, Inc. stock logo
OPTI
Optec International
N/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(COV) stock logo
COV
(COV)
N/AN/AN/A
Medicure Inc. stock logo
MPH
Medicure
2.86
2.28
1.29
Optec International, Inc. stock logo
OPTI
Optec International
N/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/A
1.46
1.46

Ownership

Institutional Ownership

CompanyInstitutional Ownership
(COV) stock logo
COV
(COV)
N/A
Medicure Inc. stock logo
MPH
Medicure
23.10%
Optec International, Inc. stock logo
OPTI
Optec International
N/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
50.13%

Insider Ownership

CompanyInsider Ownership
(COV) stock logo
COV
(COV)
N/A
Medicure Inc. stock logo
MPH
Medicure
26.99%
Optec International, Inc. stock logo
OPTI
Optec International
50.34%
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
10.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
(COV) stock logo
COV
(COV)
N/AN/AN/ANot Optionable
Medicure Inc. stock logo
MPH
Medicure
N/A10.25 millionN/ANot Optionable
Optec International, Inc. stock logo
OPTI
Optec International
111.65 millionN/ANot Optionable
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
618.96 million17.01 millionNot Optionable

TILS, PMN, MPH, COV, and OPTI Headlines

SourceHeadline
ProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93ProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93
msn.com - April 17 at 9:02 AM
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
globenewswire.com - April 9 at 7:00 AM
ProMIS Neurosciences to Present in Upcoming Investor Conferences in AprilProMIS Neurosciences to Present in Upcoming Investor Conferences in April
globenewswire.com - April 4 at 7:00 AM
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
globenewswire.com - April 1 at 4:15 PM
ProMIS Neurosciences Strengthens Global Intellectual Property PortfolioProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
globenewswire.com - March 11 at 7:00 AM
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
globenewswire.com - February 22 at 7:00 AM
Researchers discover a promising compound to treat neuropathic painResearchers discover a promising compound to treat neuropathic pain
interestingengineering.com - February 4 at 12:20 AM
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein VaccineProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
finance.yahoo.com - January 22 at 8:48 AM
ProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership TransitionProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership Transition
finanznachrichten.de - January 3 at 9:13 AM
BTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)BTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)
markets.businessinsider.com - January 3 at 9:13 AM
ProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive OfficerProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive Officer
markets.businessinsider.com - January 3 at 9:13 AM
ProMIS Neurosciences, Inc. Announces Leadership TransitionProMIS Neurosciences, Inc. Announces Leadership Transition
finance.yahoo.com - January 3 at 9:13 AM
ProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14ProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14
msn.com - November 14 at 7:10 PM
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - September 6 at 3:28 PM
ProMIS Neurosciences Inc. [PMN] Investment Appeal on the RiseProMIS Neurosciences Inc. [PMN] Investment Appeal on the Rise
knoxdaily.com - August 23 at 4:58 PM
ProMIS Neurosciences scales 31% on $20.4M private placementProMIS Neurosciences scales 31% on $20.4M private placement
msn.com - August 22 at 7:40 AM
ProMIS Neurosciences Announces $20.4 Million Private Placement FinancingProMIS Neurosciences Announces $20.4 Million Private Placement Financing
finance.yahoo.com - August 21 at 4:38 PM
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
finance.yahoo.com - May 15 at 6:49 PM
Closing Bell: Promis Neurosciences Inc down on Friday (PMN)Closing Bell: Promis Neurosciences Inc down on Friday (PMN)
theglobeandmail.com - May 6 at 8:15 AM
Closing Bell: Promis Neurosciences Inc up on Thursday (PMN)Closing Bell: Promis Neurosciences Inc up on Thursday (PMN)
theglobeandmail.com - April 27 at 10:10 PM
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s DiseaseData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
finance.yahoo.com - April 25 at 5:52 PM
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual MeetingProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
finance.yahoo.com - April 24 at 8:50 AM
Closing Bell: Promis Neurosciences Inc up on Tuesday (PMN)Closing Bell: Promis Neurosciences Inc up on Tuesday (PMN)
theglobeandmail.com - April 19 at 1:59 AM
Closing Bell: Promis Neurosciences Inc down on Monday (PMN)Closing Bell: Promis Neurosciences Inc down on Monday (PMN)
theglobeandmail.com - April 18 at 3:38 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

(COV) logo

(COV)

NYSE:COV
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.
Medicure logo

Medicure

CVE:MPH
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Optec International logo

Optec International

OTCMKTS:OPTI
Optec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California.
ProMIS Neurosciences logo

ProMIS Neurosciences

NASDAQ:PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.